Application of artemisia vulgaris in preparation of medicine for treating airway inflammation and mitochondrial dysfunction

By using ethiolin to treat asthma, significantly improve airway inflammation and protect mitochondrial function, it solves the problems that existing asthma treatment cannot cure and regulate the mechanisms that are not explored, and provides a safe and effective treatment plan.

CN119015273AInactive Publication Date: 2024-11-26YANBIAN UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411538160.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-31
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing asthma treatment methods cannot be completely cured, and their potential regulatory mechanisms have not been fully explored, resulting in insufficient prevention and treatment.

Method used

Emoflavin is used as a drug to treat airway inflammation and mitochondrial dysfunction, and provides new therapeutic means by significantly reducing the proportion of eosinophils, inhibiting inflammatory cell infiltration, upregulating antioxidant enzyme expression and protecting mitochondrial function.

Benefits of technology

Ethiol significantly improves asthma airway inflammation, enhances antioxidant systems, protects cells from oxidative damage, provides safe and effective treatment options, and provides a new direction for asthma drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015273A_ABST
    Figure CN119015273A_ABST
Patent Text Reader

Abstract

The invention provides application of artemisia vulgaris in preparation of a medicine for treating airway inflammation and mitochondrial dysfunction, and belongs to the technical field of biological medicine. The invention provides and verifies the action mechanism of the artemisia vulgaris in the asthma airway inflammation: in an HDM-induced mouse asthma model, the artemisia vulgaris obviously reduces the proportion of eosinophilic granulocytes, the infiltration of inflammatory cells around the airway, the deposition of collagenous fibers, proinflammatory factors in BALF and the level of serum IgE, and verifies the application potential of the artemisia vulgaris in the asthma; in addition, it is proved that the artemisinin can protect cells from oxidative damage by enhancing an anti-oxidation system, can significantly reduce ROS generation in cytoplasm and mitochondria, meanwhile, can up-regulate mitochondrial membrane potential, and has an important effect in the aspect of mitochondrial function protection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to the application of aflatoxin in the preparation of medicines for treating airway inflammation and mitochondrial dysfunction. Background Art

[0002] Asthma is a common chronic inflammatory airway disease, characterized by recurrent symptoms of wheezing, shortness of breath, chest tightness or coughing, which often occur or worsen at night or in the early morning. The onset of asthma is related to genetic and environmental factors, among which genetic factors mainly determine the patient's susceptible constitution, while environmental factors such as various allergens, air quality, smoking, exercise, etc. are specific triggering factors. Common types of bronchial asthma include exercise-induced, drug-induced, occupational and allergic. The symptoms of asthma are mainly wheezing, shortness of breath, chest tightness or coughing, and in severe cases, dyspnea and hypoxemia may occur.

[0003] Asthma cannot be completely cured at present, but the disease can be controlled through medication to improve the quality of life. Commonly used drugs are mainly control drugs and reliever drugs. The former are used for long-term control of the disease, such as inhaled corticosteroids, and the latter are used to relieve acute attacks, such as short-acting β2 receptor agonists. In addition, some patients with severe or refractory asthma can try non-drug treatments such as bronchial thermoplasty.

[0004] As there is no cure, prevention of asthma is particularly important. Conventional preventive measures include avoiding environments and substances that induce asthma, actively treating upper respiratory tract infections, and maintaining good living and eating habits. Although there is no cure, most asthma patients can achieve a good quality of life through regular and standardized treatment and management.

[0005] Although more and more research is being done on asthma, its potential regulatory mechanism still needs to be further explored. Therefore, this may also provide new directions for asthma treatment measures. Summary of the invention

[0006] The purpose of the present invention is to provide the use of aflatoxin in the preparation of drugs for treating airway inflammation and mitochondrial dysfunction, thereby providing a new effective means and a precise method for treating related diseases.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions: The invention provides application of edible in preparing medicine for treating airway inflammation.

[0008] The invention also provides the use of edible in preparing medicine for treating asthma.

[0009] The present invention also provides the use of aflatoxin in preparing a medicine for treating mitochondrial dysfunction.

[0010] The present invention also provides the use of aflatoxin in preparing a mitochondrial function protective agent.

[0011] Preferably, the dosage of the edible flavonoids is 50-100 mg / kg.

[0012] Preferably, the drug or mitochondrial function protective agent further comprises an auxiliary material.

[0013] Preferably, the medicine further comprises an active ingredient for preventing and treating asthma.

[0014] Preferably, the drug or mitochondrial function protective agent is in the form of powder, tablet, granule, capsule, solution, emulsion, suspension, injection, spray, aerosol or powder spray.

[0015] Preferably, the drug or mitochondrial function protective agent further comprises a pharmaceutically acceptable carrier, which includes a diluent, a buffer, a suspension, an emulsion, a granule, an encapsulation, an excipient, a filler, an adhesive, a spray, a transdermal absorbent, a wetting agent, a disintegrant, an absorption accelerator, a surfactant, a colorant, a flavoring agent or an adsorption carrier. Beneficial effects of the present invention: The present invention provides and confirms the mechanism of action of eiflavin in asthmatic airway inflammation. First, in the HDM-induced mouse asthma model, eiflavin significantly reduced the proportion of eosinophils, inflammatory cell infiltration and collagen fiber deposition around the airways, proinflammatory factors in BALF and serum IgE levels, confirming its potential in asthma. In addition, the present invention reveals that eiflavin can directly bind to and upregulate the expression of ABCG2. Considering the significant downregulation of ABCG2 in patients with severe asthma, the present invention also confirms the key mechanism of ABCG2, and observes that eiflavin treatment can significantly upregulate the expression of antioxidant enzymes Nrf2 and HO-1, increase the activity of SOD and CAT, and reduce the content of MDA. These results show that eiflavin can protect cells from oxidative damage by enhancing the antioxidant system, and can significantly reduce ROS production in the cytoplasm and mitochondria, while upregulating mitochondrial membrane potential. The present invention reveals the important role of eiflavin in protecting mitochondrial function, and provides a theoretical basis for the application of eiflavin in asthma.

[0016] Since esflavin is a natural product with good safety and lower side effects, the present invention provides a solid theoretical basis for the application of esflavin in the treatment of asthma. With further in-depth research on esflavin, esflavin is expected to become a high-quality supplementary treatment solution and provide a new means for the development of asthma drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1The results show that aflatoxin improves airway inflammation in asthmatic mice, including: (A) Flow chart of mouse modeling. (B) Flow cytometry detection of CD3+ and Siglec-F+ cells in BALF of different treatment groups. (C) HE, PAS and Masson staining show the pathological changes of airway tissues in mice of different groups. (D) IL-4, IL-5 and IL-13 cytokine levels in BALF. (E) Serum total IgE and HDM-specific IgE levels. (F) IFN-γ and IL-4 expression levels in BALF. In statistical analysis, all data are expressed as mean ± standard deviation (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001; Figure 2 The results show that aflatin exerts its effects by directly binding to and upregulating ABCG2, where: (A) Bioinformatics analysis predicts potential binding targets of aflatin (B) GEO dataset (GSE43696) analysis shows differential expression of ABCG2 in normal control (NC), mild to moderate asthma (MMA) and severe asthma (SA) patients. (C) Protein-small molecule docking test verification (D) Aflatin molecular structure and its structure after biotin labeling. (E) Drug affinity reaction table stability (DARTS) test (F) Pull-Down experiment (G) Cellular thermal shift assay (CETSA) (H) Immunohistochemistry to observe ABCG2 expression in lung tissue of mice treated with aflatin (I) MTT experiment determines the appropriate concentration of aflatin in cell experiments. (J) Western blot (WB) experiment to observe the expression of ABCG2 protein after aflatin treatment (K) Observation of co-localization of aflatin labeled with biotin and ABCG2 in cells. In statistical analysis, all data are expressed as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001; Figure 3The results show that aflatoxin inhibits HDM-induced oxidative stress and alleviates airway inflammation in asthmatic mice by regulating ABCG2, where: (A) Western blot shows the effects of ABCG2 overexpression and aflatoxin treatment on the expression of iNOS and NOX2 in HDM-induced mouse lung tissue. (B) Determination of ROS, MDA, SOD, GSH and CAT levels in BALF of mice in each group. (C) Flow cytometry was used to detect the level of ROS in BALF of mice in each group. (D) Fluorescence analysis of mtROS in cells. (E) JC-1 staining showed the changes in mitochondrial membrane potential in cells in each group. (F) MitoTracker staining showed the changes in mitochondrial morphology in cells in each group. In statistical analysis, all data are expressed as mean ± standard deviation (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001; Figure 4 Figure 1 shows that aflatoxin inhibits HDM-induced activation of Drp1 and improves mitochondrial morphology in BEAS-2B cells by regulating ABCG2, where: (A) Immunofluorescence staining shows the localization and expression of ABCG2 and MitoTracker in different treatment groups. (B) Western blot analysis of the expression levels of Drp1, p-Drp1 and MFN2 in different treatment groups. (C) TOM20 immunofluorescence staining shows changes in mitochondrial morphology. (D) JC-1 staining shows changes in mitochondrial membrane potential in different treatment groups. (E) Immunofluorescence staining shows the expression levels of mtSOX in different treatment groups. (F) DCFH-DA staining shows changes in ROS levels in different treatment groups. (G) Transmission electron microscopy (TEM) shows changes in mitochondrial morphology in different treatment groups. (H) Western blot analysis of the expression levels of Drp1, p-Drp1 and MFN2 in different treatment groups. (I) Immunofluorescence staining shows the localization and expression of Drp1 and MitoTracker in different treatment groups. In statistical analysis, all data are expressed as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001; Figure 5Figure 1 shows that aflatin inhibits the activation of Drp1 in HDM-induced BEAS-2B cells by regulating the ABCG2 / Rab7a pathway, where: (A) PPI network analysis shows proteins that interact with ABCG2. (B) Molecular docking analysis shows the interaction region between ABCG2 and Rab7a. (C) Immunofluorescence staining shows the localization and expression of Rab7a, MitoTracker and Drp1 in different treatment groups. (D) Immunohistochemical staining shows the expression of Rab7a in different treatment groups. (E) CO-IP experiment shows the interaction between ABCG2 and Rab7a. (F) Western blot analysis of the expression level of Rab7a in different treatment groups. (G) Western blot analysis of the expression level of Drp1, p-Drp1 and MFN2 in different treatment groups. (H) Immunofluorescence staining shows the localization and expression of Drp1 and MitoTracker in different treatment groups. (I) JC-1 staining shows the changes in mitochondrial membrane potential in different treatment groups. (J) Immunofluorescence staining showed the expression level of mtSOX in different treatment groups. (K) DCFH-DA staining showed the changes in ROS levels in different treatment groups. In statistical analysis, all data are expressed as mean ± standard deviation (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001; Figure 6 The results show that aflatoxin alleviates apoptosis through ABCG2, where: (A) Gene expression analysis shows the role of ABCG2 in the cell apoptosis pathway. (B) TUNEL staining shows the number of apoptotic cells in different treatment groups. (C) Flow cytometry analysis shows the percentage of apoptotic cells in different treatment groups. (D) Western blot analysis shows the expression levels of proteins related to PANoptosome, pyroptosis, apoptosis, and necroptosis in different treatment groups. In statistical analysis, all data are expressed as mean ± standard deviation (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001. DETAILED DESCRIPTION

[0018] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0019] The CAS number of the edible in the present invention is 479-90-3, which was purchased from MedChemExpress (MCE). Example 1

[0020] Materials and methods 1. Mice Six-week-old BALB / c female mice (weight range 18-22 g) were purchased from Yanbian University Medical College. The mice were housed in a specific pathogen-free environment at a temperature of (22 ± 2) °C, relative humidity maintained at 50% to 60%, and a 12-h light-dark cycle. All animal experimental procedures were approved by the Animal Care and Utilization Committee of Yanbian University. (Approval number: YD20230710003).

[0021] 2. HDM-induced asthma mouse model Mice were sensitized with 50 µg HDM (#XPB46D3A4, GreerLaboratories, Lenoir, NC, USA) by intranasal instillation on day 0. From day 7, mice were challenged with 50 µg HDM daily by intranasal instillation until day 11 to aggravate airway allergic reactions. Treatment groups were treated with 50 mg / kg and 100 mg / kg aflatoxin by intraperitoneal injection starting on day 7. All mice were euthanized by injection of 100 mg / kg sodium pentobarbital 24 days after the end of the experiment. Serum, lung tissue, bronchoalveolar lavage fluid (BALF), and lymph nodes were quickly collected.

[0022] 3. Flow Cytometry To detect Th2 cytokine expression in mediastinal lymph nodes (mLN), the collected mLN single cell suspension was first stained with PE-CD4 antibody. Then, intracellular fixation and permeabilization were performed, and intracellular antibodies including PE-CY7-IFN-γ antibody (25-7311-82, Invitrogen) and APC-IL-4 antibody (554436, BD) were used to stain the ratio of IL-4+CD4+ cells and IFN-γ+CD4+ cells. The phenotype of eosinophils in BALF was defined as CD45.2+CD11c-siglec-F+. Regarding apoptosis, the Annexin-V apoptosis detection kit provided by BD Biosciences (CA, USA) was used and the proportion of 7-AAD+Annexin-V+ cells was analyzed. All samples were detected using a Cytoflex flow cytometer from Beckman Coulter, Inc (CA, USA) and analyzed using Cytoexpert 2.4 software.

[0023] 4. Drug Affinity Response Target Stability (DARTS) Test After protein lysis, the cells were diluted 1:10 with TNC buffer and aflatoxin (50 μM) or DMSO (control) was added. The cells were incubated at room temperature for 2 h, and proteinase (25 ug / mL) was added and incubated at 37°C for 30 min. Western blot analysis was performed using anti-ABCG2 antibody.

[0024] 5. Thermal stability analysis (CETSA test) BEAS-2B cells were treated with 10 μM aflatin for 30 minutes. The cells were incubated at different temperatures (37°C to 72°C) for 10 minutes to induce thermal denaturation of proteins. After the reaction, the cells were quickly cooled and total proteins were extracted for Western blot analysis.

[0025] 6. MTT assay MTT solution (0.5 mg / mL, C0009S, Beyotime, China) was used according to the manufacturer's instructions. Cell viability = (OD value of aflatoxin-treated cells / OD value of control cells) × 100%.

[0026] 7. Mitochondrial membrane potential detection The cells were incubated with fluorescent probe JC-1 (Beyotime) at 37°C in the dark for 20 min, and then washed twice and the fluorescence signal was collected using the Cytation5 cell imaging microplate detection system (BioTek, Winooski, VT, USA).

[0027] 8. Docking Analysis To evaluate the binding affinity between artemetin and ABCG2, first, the molecular structure of artemetin was obtained from the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov / ), and the ABCG2 protein (PDB ID: 6VXF; resolution, 3.5 Å) was downloaded from the RCSB Protein Data Bank. Molecular docking was performed using AutoDockTools-1.5.7 software. Regarding the protein-protein interaction between ABCG2 and RAB7A (downloaded from https: / / www.ebi.ac.uk / pdbe / entry / pdb / 1t91 / protein / 1), ZDOCK 3.0.2 software was used for docking. All docking results were visualized by PyMOL software.

[0028] 9. Transmission Electron Microscopy BEAS-2B cells from different treatment groups were washed, trypsinized, and fixed with glutaraldehyde overnight at 4°C. Then, they were post-fixed in 1% osmium tetroxide in bicarbonate buffer and dehydrated in a series of ethanol solutions. Finally, the samples from each group were embedded in Poly / Bed 812 resin to observe the ultrastructure of mitochondria under transmission electron microscopy.

[0029] 10.ROS detection To detect ROS in cells and tissues, DCFH-DA fluorescent probe (10 μM, Catalog No. S0033S, Beyotime, Shanghai, China) was used for incubation at 37°C for 10 min. For mitochondrial ROS (mtROS) detection, cells were incubated with MitoSOX dye (5 μM, Catalog No. M36008, Thermo Fisher Scientific, Massachusetts, USA) for 10 min at 37°C. Images were acquired by Cytation 5. All data were normalized to the control group.

[0030] 11. Cell Transfection Plasmids targeting ABCG2 gene overexpression and siRNA targeting RAB7A were purchased from GenePharma (Shanghai, China). BEAS-2B cells were transfected using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). The medium was changed on the first day after transfection. Cells were harvested on the second day after transfection for subsequent experiments.

[0031] 12. Histological Analysis Lung tissue was stained with hematoxylin and eosin (G1120, Solarbio, Beijing, China) to observe the infiltration of inflammatory cells. At the same time, PAS staining was performed using the glycogen PAS staining solution kit (G1281, Solarbio) to analyze the proliferation of goblet cells around the airways and the secretion of airway mucus. Masson staining (G1340, Solarbio) was used to distinguish collagen fibers from elastic fibers.

[0032] 13. Immunohistochemistry First, lung tissue sections were dewaxed and dehydrated in graded ethanol. Next, antigen retrieval was performed with citric acid buffer. Then, sections were incubated with rabbit anti-ABCG2 antibody (AF5177, Affinity, USA) and rabbit anti-RAB7A antibody (PA5-78238, Thermofisher, USA), followed by secondary antibody incubation with goat anti-rabbit IgG H&L (HRP) (6721, Abcam, USA). After staining, images were captured using an optical microscope (Eclipse Ni-U, Nikon, Japan).

[0033] 14. Immunofluorescence detection Lung tissue sections were dewaxed, dehydrated in graded ethanol, and antigen retrieval and blocking were performed with citrate buffer. To label mitochondria, sections and cells were pre-incubated with MitoTracker Red (100 mM, #M7512, Thermo) probe at 37°C for 30 min. Then, sections were incubated with ABCG2 antibody (AF5177), RAB7A antibody (PA5-78238), tom20 antibody (#ab186735, Abcam, USA), and rabbit anti-DRP1 (8570S, CST, USA) at 4°C overnight. The next day, after washing with PBS, sections were incubated with AlexaFluor488 goat anti-rabbit antibody (R37118, Life Technologies, USA) and goat anti-mouse IgG HampLCy3® (97035, Abcam, USA) at room temperature for 2 h. Finally, cell nuclei were stained with DAPI. Samples were observed and images were taken under a fluorescence microscope.

[0034] 15. Synthesis of Biotin-Artemetin (bio-ART) Weigh 40 mg of Artemetin and dissolve it in 3 mL of DMF. Add Biotin (1.0 eq.), HOBT reagent (1.5 eq.), DIC (1.5 eq.) and DMAP (0.3 eq.) and dissolve them completely. React at room temperature for 4 h, concentrate under reduced pressure, purify by column chromatography (dichloromethane: methanol = 20:1), concentrate the ether precipitate under reduced pressure, collect the precipitate by centrifugation, and dry in vacuo to obtain Biotin-Artemetin.

[0035] 16. Western Blot Assay First, total lung tissue protein was extracted using RIPA lysis buffer (containing protease inhibitors). After the protein concentration was determined by nano micro-spectrophotometer (NanoPhotometer NP80® Implen (Bavaria, Munich, Germany)), equal amounts of protein (20 μg / well) were separated by SDS-PAGE electrophoresis, transferred to PVDF membrane (100 V, 90 min), blocked, and then incubated with β-actin (3700S, CST, USA), FADD (A19838, Abclonal, China) RAB7A (55469-1-AP, PeproTech, USA), bcl-2 (AF6139, Affinity, USA), GSDMD (A18281, Abclonal, China), NRF2 (SAB4501984, Sigma, USA), ABCG2 (AF5177, Affinity, USA), RIPK1 / RIP (A7414, Abclonal, China), p-DRP1 (3455S, CST, USA), and DRP1 (55469-1-AP, PeproTech, USA). (8570S, CST, USA), cleaved-caspase 8 (9496S, CST, USA), ZBP (A1517, Abclonal, China), MFN-2 (rabbit) (9482S, CST, USA), Heme Oxygenase 1 (ab189491, Abcam, UK) and BAX (2772, CST, USA) were incubated at 4°C overnight. The next day, after washing with TBST, the cells were incubated with HRP-goat anti-rabbit antibody (6789, Abcam) and HRP-mouse anti-antibody (97080, Abcam) respectively. Incubate at room temperature for 1 hour. The enhanced chemiluminescence (ECL) kit was used for development, and images were collected on a chemiluminescence imaging system (GE, USA). The grayscale analysis of the bands was performed using Image J software, and relative quantification was performed using β-actin as an internal reference.

[0036] 17. Statistical Analysis The significant differences among the groups were analyzed by ANOVA or Wilcoxon rank sum test. All data are expressed as mean ± standard deviation (SD), and P < 0.05 was considered statistically significant.

[0037] Experimental results: F1. Aflatoxin significantly relieves asthma airway inflammation First, an asthma model was established by inducing HDM in mice ( Figure 1A). Flow cytometry analysis showed that the proportion of eosinophils (CD45.2+CD11c-siglec-F+) in the HDM group was significantly higher than that in the control group ( Figure 1 B). After treatment with aflatoxin, the proportion of eosinophils in the model group was significantly lower than that in the HDM group. Then, HE, PAS and Masson staining were performed on the paraffin sections of the mouse lung tissues, and it was observed that the inflammatory cell infiltration, airway epithelial mucus secretion and collagen fiber deposition in the lung tissues of the mice treated with aflatoxin were significantly reduced ( Figure 1 C). Subsequently, the results of ELISA tests showed that the levels of pro-inflammatory cytokines (such as IL-4, IL-5, and IL-13) in BALF and serum IgE in the mice treated with aflatoxin were significantly reduced ( Figure 1 D, E). In addition, it was found that aflatoxin could significantly improve the expression level of IFN-γ in the mediastinal lymph nodes of the asthma model, and effectively inhibit the increase of IL-4 ( Figure 1 F). These results further illustrate the inhibitory effect of edible flavonoids on HDM-induced asthmatic airway inflammation.

[0038] F2. Aflatoxin exerts its effects by directly binding to and upregulating ABCG2 Through bioinformatics analysis, the potential binding targets of aflatoxin were predicted, and the results showed that the target with the highest correlation was ABCG2 ( Figure 2 A). Subsequently, differential expression analysis of ABCG2 was performed between normal controls (NC), mild-to-moderate asthma (MMA), and severe asthma (SA) patients using the geo dataset (GSE43696). The results showed that ABCG2 was significantly downregulated in severe asthma patients ( Figure 2 B), which indicates the significant relevance of ABCG2 in asthma. Subsequently, the high affinity between aflatoxin and ABCG2 was verified by protein-small molecule docking experiment ( Figure 2 C). To further verify these ideas, a biotin tag was added to the aflatoxin molecule ( Figure 2 D, and the stability of the binding was evaluated by the drug affinity response target stability (DARTS) test. The results showed that the stability of ABCG2 was significantly improved after aflatoxin treatment ( Figure 2 E). Similarly, in the Pull-Down experiment, aflatoxin was able to successfully capture ABCG2, which further supported the direct binding relationship between the two ( Figure 2 F). Finally, in the cell thermal drift assay (CETSA), it was found that aflatoxin significantly improved the thermal stability of ABCG2 ( Figure 2 G). This further verifies the high affinity between the two.

[0039] Furthermore, the effect of aflatoxin on the expression of ABCG2 was evaluated. The results of immunohistochemistry showed that the expression of ABCG2 in the lung tissue of mice in the aflatoxin treatment group was significantly upregulated ( Figure 2 H). Subsequently, the appropriate concentration of aflatoxin in the cell experiment was determined by MTT experiment ( Figure 2 I). Western blot (WB) experiments further verified that aflatoxin treatment significantly upregulated the expression of ABCG2 protein in cells ( Figure 2 J). Similarly, a cell co-localization experiment was performed on biotin-tagged aflatin and ABCG2, and it was found that its co-localization with aflatin was significantly increased, which further supported the direct interaction between aflatin and ABCG2 ( Figure 2 K).

[0040] F3. Aflatoxin inhibits ROS production and upregulates mitochondrial membrane potential in HDM-treated BEAS-2B cells by targeting ABCG2 After verifying the binding of aflatoxin to ABCG2, its mechanism of action was further explored. HDM stimulation was performed using the BEAS-2B cell line overexpressing ABCG2 to detect its effect on oxidative stress. WB test results showed that aflatoxin treatment significantly upregulated the expression of antioxidant enzymes Nrf2 and HO-1 ( Figure 3 A). ELISA test results showed that aflatoxin treatment significantly increased the activities of SOD and CAT in the lung tissue of mice, and significantly reduced the content of MDA ( Figure 3 B). In addition, in flow cytometry, it was found that aflatoxin treatment significantly inhibited ROS production in HDM-treated BEAS-2B cells ( Figure 3 C). The results of detecting mitochondrial ROS by mtSOX showed that aflatoxin treatment significantly reduced the production of mtROS ( Figure 3 D). To evaluate the effect of aflatoxin on mitochondrial membrane potential, JC-1 staining was used to detect mitochondrial membrane potential in cells ( Figure 3 E). The results showed that the fluorescence of aggregates in the cells treated with aflatoxin was significantly enhanced, while the fluorescence of monomers was significantly reduced, indicating that aflatoxin could upregulate mitochondrial membrane potential. In addition, the mitochondrial morphology observed using the MitoTracker-red fluorescent probe showed that mitochondrial fragmentation was reduced after aflatoxin treatment ( Figure 3 F). These results further support that aflatoxin alleviates mitochondrial oxidative stress and protects mitochondrial function through ABCG2.

[0041] F4. Aiflavin inhibits the expression of p-Drp1 and reduces mitochondrial fission by targeting ABCG2 In the present invention, immunofluorescence double staining was used to observe that the colocalization of ABCG2 and MitoTracker-red was significantly enhanced in lung tissue treated with aflatoxin. This result suggests that aflatoxin may affect mitochondrial function by targeting ABCG2 ( Figure 4 A). Further Western blot analysis showed that aflatin treatment significantly reduced the expression of mitochondrial fission protein p-Drp1, while the expression of total Drp1 did not change significantly. In addition, the expression of fusion protein MFN2 was significantly upregulated. When aflatin was used in combination with the p-Drp1 inhibitor Mdivi-1, the expression of both p-Drp1 and MFN2 returned to normal levels ( Figure 4 B). Tom20 fluorescence staining revealed that even in the absence of Mdivi-1, aflatoxin treatment could reduce some mitochondrial fission ( Figure 4 C). In addition, the combination of aflatoxin and Mdivi-1 induced a decrease in the monomeric form of JC-1, indicating an increase in mitochondrial membrane potential ( Figure 4 D). Furthermore, the combination of aflatoxin and Mdivi-1 significantly reduced the levels of ROS in the cytosol and reactive oxygen species in the mitochondria ( Figure 4 E, F) Electron microscopy showed that the combined use of aflatoxin and Mdivi-1 could significantly improve HDM-induced mitochondrial damage, including mitochondrial swelling, inner membrane shrinkage, and decreased matrix density ( Figure 4 G). The results of the co-localization experiment of MitoTracker-red and Drp1 showed that the co-localization of mitochondria and Drp1 was significantly reduced after treatment with aflatoxin and overexpression of ABCG2 ( Figure 4 H). In the experiment of the combined action of drugs and ABCG2, it was observed that aflatoxin and overexpression of ABCG2 significantly inhibited the expression of p-Drp1 and significantly upregulated the expression of MFN2 ( Figure 4 I). In summary, the present invention demonstrates that aflatoxin upregulates ABCG2, inhibits the expression of p-Drp1 in HDM-treated BEAS-2B cells, reduces mitochondrial fission, and thus protects mitochondrial function.

[0042] F5. Aflatoxin reduces p-DRP1 expression in airway epithelial cells by stabilizing the ABCG2 / RAB7A pathway Through PPI network analysis (https: / / omics.bjcancer.org / ) Figure 5 A), it was noted that the mitochondrial-associated protein RAB7A can bind to ABCG2. Protein-protein molecular docking analysis showed that RAB7A has a high affinity with ABCG2 ( Figure 5B). The immunohistochemical double staining experiment showed that the co-localization of RAB7A and MitoTracker-red was significantly enhanced in the aflatoxin treatment group, and aflatoxin treatment could downregulate the translocation of RAB7A to mitochondria ( Figure 5 C). Immunohistochemical analysis showed that aflatoxin significantly reduced the expression of RAB7A in lung tissue ( Figure 5 D). Further co-IP experiments showed that RAB7A may be recruited by ABCG2 ( Figure 5 E). In addition, Western blot analysis results showed that aflatoxin treatment significantly downregulated the expression of RAB7A, especially in the case of overexpression of ABCG2, the downregulation of RAB7A was more obvious ( Figure 5 F). This suggests that aflatoxin exerts its effects by regulating the ABCG2 / RAB7A pathway. To further verify the relationship between RAB7A and p-DRP1, RAB7A was knocked down and its effect on p-DRP1 expression was observed. The results showed that RAB7A knockdown significantly increased the inhibitory effect of aflatoxin on p-DRP1 expression and the upregulation of MFN2 expression ( Figure 5 G). Then, through the MitoTracker-red fluorescent probe and DRP1 double staining experiment, it was observed that RAB7A knockdown significantly increased the inhibitory effect of aflatoxin on DRP1 expression in mitochondria ( Figure 5 H). In addition, RAB7A knockdown significantly enhanced the upregulation of mitochondrial membrane potential by aflatoxin ( Figure 5 I) and significantly enhanced the inhibitory effect of aflatoxin on ROS ( Figure 5 J, K). These results suggest that aflatoxin plays a key role in alleviating mitochondrial fission and oxidative stress through ABCG2 / RAB7A.

[0043] F6. Aflatoxin alleviates pan-apoptosis via ABCG2 In the present invention, KEGG analysis was performed on ABCG2-related proteins, and it was found that they were significantly associated with the necroptosis pathway ( Figure 6 A). To clarify the mechanism of action of aflatoxin on apoptosis, firstly, TUNEL colorimetry and flow cytometry were used to detect cell apoptosis. The results showed that aflatoxin treatment significantly reduced the number of apoptotic cells ( Figure 6B, C). WB results showed that in the HDM-induced BEAS-2B cell model, ABCG2 was overexpressed, and the activity of PANoptosis in the aflatoxin group was significantly reduced, specifically manifested by decreased levels of pyroptotic GSDMD, decreased levels of apoptotic Caspase-8 and BAX, increased levels of anti-apoptotic protein Bcl-2, and decreased expression of necroptosis markers P-RIPK1, RIPK1, and FADD. Next, RAB7A was knocked down in the HDM-stimulated cell model, and similar results were obtained. In summary, aflatoxin has a significant effect in reducing HDM-induced PANoptosis through ABCG2.

[0044] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of aflatoxin in the preparation of drugs for treating airway inflammation.

2. Application of aflatoxin in the preparation of drugs for treating asthma.

3. Application of aflatoxin in the preparation of drugs for the treatment of mitochondrial dysfunction.

4. Application of aflatoxin in the preparation of mitochondrial function protective agents.

5. The use according to any one of claims 1 to 4, characterized in that: The dosage of the edible flavonoids is 50-100 mg / kg.

6. The use according to any one of claims 1 to 4, characterized in that: The drug or mitochondrial function protective agent further comprises auxiliary materials.

7. The use according to claim 2, characterized in that: The medicament also contains an active ingredient for preventing and treating asthma.

8. The use according to any one of claims 1 to 4, characterized in that: The dosage form of the drug or mitochondrial function protective agent is powder, tablet, granule, capsule, solution, emulsion, suspension, injection, spray, aerosol or powder spray.

9. The use according to claim 8, characterized in that: The drug or mitochondrial function protective agent further comprises a pharmaceutically acceptable carrier, which includes a diluent, a buffer, a suspension, an emulsion, a granule, an encapsulation agent, an excipient, a filler, an adhesive, a spray, a transdermal absorbent, a wetting agent, a disintegrant, an absorption accelerator, a surfactant, a colorant, a flavoring agent or an adsorption carrier.

Citation Information

Patent Citations

  • Artemisetin medicine application

    CN107375264A